40503-90-0

Basic information

• Product Name: 4-(4-Methylphenyl)cyclohexanone
• Synonyms: 4-(4-Methylphenyl)cyclohexanone;4-(4-Methylphenyl)cyclohexan-1-one;4-p-tolyl cyclohexanone;4-(p-Tolyl)cyclohexanone
• CAS NO: 40503-90-0
• Molecular Formula: C₁₃H₁₆O
• Molecular Weight: 188.268
• Mol File: 40503-90-0.mol

Chemical Properties

• Melting Point: 49.0 to 53.0 °C
• Boiling Point: 313.851°C at 760 mmHg
• Flash Point: 133.339°C
• Appearance: /
• Density: 1.026
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-(4-Methylphenyl)cyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylphenyl)cyclohexanone(40503-90-0)
• EPA Substance Registry System: 4-(4-Methylphenyl)cyclohexanone(40503-90-0)

Safety Data

• Hazardous Substances Data: 40503-90-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Methylphenyl)cyclohexanone is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its reactivity and versatility allow for the creation of a wide range of organic molecules, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(4-Methylphenyl)cyclohexanone serves as a crucial building block in the production of various agrochemicals. Its role in the synthesis of these compounds aids in the development of effective pesticides, herbicides, and other agricultural chemicals.
Used in Organic Synthesis:
4-(4-Methylphenyl)cyclohexanone is utilized as a versatile reagent in organic synthesis. Its capacity to undergo multiple chemical transformations makes it an indispensable tool for researchers and chemists working on the development of new organic compounds and materials.
Used in Research:
4-(4-Methylphenyl)cyclohexanone is also employed in various research applications, where its properties and reactions are studied to gain insights into organic chemistry and to develop new synthetic methodologies and techniques.

InChI:InChI=1/C13H16O/c1-10-2-4-11(5-3-10)12-6-8-13(14)9-7-12/h2-5,12H,6-9H2,1H3

Upstream product

• 36716-70-8 4-hydroxy-4-(p-tolyl)cyclohexan-1-one 
• 36716-74-2 4'-methyl-2,5-dihydro-[1,1'-biphenyl]-4(3H)-one 
• 106-38-7 para-bromotoluene 
• 5720-05-8 4-methylphenylboronic acid 
• 146631-00-7 [4-(benzyloxy)phenyl]boronic acid 
• 6793-92-6 p-benzyloxyphenylbromide 
• 680596-79-6 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 
• 170011-47-9 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 365553-53-3 8-(p-tolyl)-1,4-dioxaspiro[4.5]decan-8-ol 
• 365553-55-5 8-(4-methyl-phenyl)-1,4-dioxaspiro[4.5]dec-7-ene 
• 174911-69-4 8-p-tolyl-1,4-dioxa-spiro[4.5]decane 

Downstream Products

• 868142-01-2 8-p-tolyl-1,3-diaza-spiro[4.5]decane-2,4-dione 
• 1297474-41-9 C₁₆H₁₄N₂OS 
• 1297474-52-2 C₂₀H₁₄N₂O₂S 
• 1297474-17-9 C₂₀H₁₆N₂O₃S 
• 1297474-32-8 C₁₆H₁₈N₂OS 
• 1393641-24-1 (S)-4-(4-methylphenyl)cycloheptan-1-one 
• 1402080-46-9 5-(p-tolyl)oxepan-2-one 

Relevant articles and documents

Preparation method of trans-ketone intermediate

The invention discloses a preparation method of trans-ketone intermediates. The trans-ketone intermediates comprise compounds as shown in a formula (I) and a formula (II). The preparation process comprises the following steps: (1) performing catalytic hydrogenation on the compounds as shown in the formula (I) to prepare ketone intermediate products; (2) preparing a Grignard reagent from benzyloxy halogenated benzene and magnesium powder, and performing acidolysis dehydration on the Grignard reagent and the ketone intermediate product prepared in the step (1) to obtain a compound as shown in a formula (II); and (3) carrying out catalytic hydrogenation and isomerization reaction on the compound as shown in the formula (II) prepared in the step (2). According to the preparation method provided by the invention, the technical problem that multiple benzyl alcohol impurities and impurity products after ketone condensation exist in acidolysis dehydration products of dicyclohexanone ethylene monoketal adopted in a traditional process is solved, and the purification difficulty of trans-ketone intermediate products is greatly reduced.

Synthesis method of 4-substituent cyclohexanone liquid crystal intermediate

The invention discloses a synthesis method of a 4-substituent cyclohexanone liquid crystal intermediate, which comprises the following step: carrying out oxidation catalytic reaction on 4-substituent cyclohexanol under the action of trichloroisocyanide urea to obtain the 4-substituent cyclohexanone liquid crystal intermediate. The method is high in reaction selectivity, high in yield, environment-friendly, simple in post-treatment and suitable for industrial production.

NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES

Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo [1, 5-a] pyridines that can be useful for inhibiting indoleamine 2, 3-dioxygenase and/or tryptophane 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

Enantioselective Synthesis of Chiral Oxime Ethers: Desymmetrization and Dynamic Kinetic Resolution of Substituted Cyclohexanones

Axially chiral cyclohexylidene oxime ethers exhibit unique chirality because of the restricted rotation of C=N. The first catalytic enantioselective synthesis of novel axially chiral cyclohexylidene oximes has been developed by catalytic desymmetrization of 4-substituted cyclohexanones with O-arylhydroxylamines and is catalyzed by a chiral BINOL-derived strontium phosphate with excellent yields and good enantioselectivities. In addition, chiral BINOL-derived phosphoric acid catalyzed dynamic kinetic resolution of α-substituted cyclohexanones has been performed and yields versatile intermediates in high yields and enantioselectivities.

Optimization of TRPV6 calcium channel inhibitors using a 3D ligand-based virtual screening method

Herein, we report the discovery of the first potent and selective inhibitor of TRPV6, a calcium channel overexpressed in breast and prostate cancer, and its use to test the effect of blocking TRPV6-mediated Ca2+-influx on cell growth. The inhib

Design and synthesis of novel small molecule CCR2 antagonists: Evaluation of 4-aminopiperidine derivatives

A novel N-(2-oxo-2-(piperidin-4-ylamino)ethyl)-3-(trifluoromethyl)benzamide series of human CCR2 chemokine receptor antagonists was identified. With a pharmacophore model based on known CCR2 antagonists a new core scaffold was designed, analogues of it synthesized and structure-affinity relationship studies derived yielding a new high affinity CCR2 antagonist N-(2-((1-(4-(3-methoxyphenyl)cyclohexyl)piperidin-4-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide.

Enantioselective baeyer-villiger oxidation: Desymmetrization of meso cyclic ketones and kinetic resolution of racemic 2-arylcyclohexanones

Catalytic enantioselective Baeyer-Villiger (BV) oxidations of racemic and meso cyclic ketones were achieved in the presence of chiral N,N'-dioxide-Sc III complex catalysts. The BV oxidations of prochiral cyclohexanones and cyclobutanones afforded series of optically active μ- and γ-lactones, respectively, in up to 99% yield and 95% ee. Meanwhile, the kinetic resolution of racemic 2-arylcyclohexanones was also realized via an abnormal BV oxidation. Enantioenriched 3-aryloxepan-2-ones, whose formation is counter to the migratory aptitude, were obtained preferentially. Both the lactones and the unreacted ketones were obtained with high ee values.

Enantioselective baeyer-villiger oxidation: Desymmetrization of meso cyclic ketones and kinetic resolution of racemic 2-arylcyclohexanones

Catalytic enantioselective Baeyer-Villiger (BV) oxidations of racemic and meso cyclic ketones were achieved in the presence of chiral N,N'-dioxide-Sc III complex catalysts. The BV oxidations of prochiral cyclohexanones and cyclobutanones afforded series of optically active μ- and γ-lactones, respectively, in up to 99% yield and 95% ee. Meanwhile, the kinetic resolution of racemic 2-arylcyclohexanones was also realized via an abnormal BV oxidation. Enantioenriched 3-aryloxepan-2-ones, whose formation is counter to the migratory aptitude, were obtained preferentially. Both the lactones and the unreacted ketones were obtained with high ee values.

Aryl extensions of thienopyrimidinones as fibroblast growth factor receptor 1 kinase inhibitors

Optimization of thienopyrimidinone derivatives as FGFR1 kinase inhibitors is being pursued. The present results confirm predictions of computational modeling that an aryl substituent can be introduced at the 2-position in structure 3. The substituent is anticipated to project deeper into the binding site and provide opportunities for enhanced activity and selectivity. The most potent analog reported herein, 13, has a 4-hydroxyphenyl substituent and yields an IC50 of 6 μM for inhibition of phosphorylation by FGFR1 kinase. It was also found that the western anisole-containing substituent in 3 can be replaced by a propionic acid group with no loss in potency and with potentially significant gains in pharmacologically relevant properties.